Clarus Keeping Commercial Options Open For Oral Testosterone Jatenzo
Jatenzo – the first oral testosterone cleared by US FDA – will compete against injectable and topical formulas in a field that has suffered safety worries in the past. Clarus has a jump on oral rival Lipocine.
You may also be interested in...
The latest drug development news and highlights from our US FDA Performance Tracker.
US FDA advisory committee worries about off-label use of Lipocine's Tlando and Clarus' Jatenzo.
Advisory committees also vote to change indication of testosterone replacement therapies, saying new trials are needed if sponsors want to win the old claims back.